<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=us-ascii">
<meta name="Generator" content="Microsoft Word 15 (filtered medium)">
<style><!--
/* Font Definitions */
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Palatino;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0in;
margin-bottom:.0001pt;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:#0563C1;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:#954F72;
text-decoration:underline;}
span.EmailStyle17
{mso-style-type:personal-compose;
font-family:"Calibri",sans-serif;
color:windowtext;}
.MsoChpDefault
{mso-style-type:export-only;
font-family:"Calibri",sans-serif;}
@page WordSection1
{size:8.5in 11.0in;
margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
{page:WordSection1;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]-->
</head>
<body lang="EN-US" link="#0563C1" vlink="#954F72">
<div class="WordSection1">
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-19-363.html__;!5Xm4_O-4tfk!lot7OkGX4V_KPbVj0ANCKif2DAw2-sP_FIeyTxIuNSGyExmCTAAtut4P3fiJkmebjOoekAyc6M811ZDgQ3E$" target="_blank"><span style="color:#0563C1">Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy
(R01 Clinical Trial Optional)</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) seeks research project (R01) grant applications describing projects that integrate imaging and
fluid-based tumor monitoring (liquid biopsy) assays during cancer therapy in patients to determine the optimal use of those modalities in the characterization of therapy response and/or emergence of resistance.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Standard dates apply. Expires May 8, 2021.
<span style="color:red">Med-RA deadline to receive draft documents for October 2019 standard date: September 23, 2019.</span></span></b><o:p></o:p></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Intervening with Cancer Caregivers to Improve Patient Health Outcomes and Optimize Health Care Utilization (R21 / R01 Clinical Trial Optional)<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-19-355.html__;!5Xm4_O-4tfk!lot7OkGX4V_KPbVj0ANCKif2DAw2-sP_FIeyTxIuNSGyExmCTAAtut4P3fiJkmebjOoekAyc6M81U0BGGsU$" target="_blank"><span style="color:#0563C1">R21</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/par-19-352.html__;!5Xm4_O-4tfk!lot7OkGX4V_KPbVj0ANCKif2DAw2-sP_FIeyTxIuNSGyExmCTAAtut4P3fiJkmebjOoekAyc6M8127h5y3c$" target="_blank"><span style="color:#0563C1">R01</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">These Funding Opportunity Announcements (FOAs) invite applications for intervention research designed to support caregivers of adult cancer patients. Interventions supported by these FOAs
are intended to provide caregivers with care training, promote coping skills, and ultimately help them manage care. Outcomes of such interventions are expected to (1) optimize patient health care utilization, (2) improve caregiver well-being, and (3) improve
patient physical health and psychosocial outcomes.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">First due date for R21: October 16, 2019. First due date for R01: October 17, 2019. Then standard dates apply. Expires September 8, 2022.
<span style="color:red">Med-RA deadline to receive draft documents for October 2019 due dates: October 3, 2019.</span></span></b><o:p></o:p></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R03 / R21 / R01 Clinical Trial Optional)<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/par-19-359.html__;!5Xm4_O-4tfk!lot7OkGX4V_KPbVj0ANCKif2DAw2-sP_FIeyTxIuNSGyExmCTAAtut4P3fiJkmebjOoekAyc6M81XR4TOz0$" target="_blank"><span style="color:#0563C1">R03</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/par-19-358.html__;!5Xm4_O-4tfk!lot7OkGX4V_KPbVj0ANCKif2DAw2-sP_FIeyTxIuNSGyExmCTAAtut4P3fiJkmebjOoekAyc6M81YQX9XGo$" target="_blank"><span style="color:#0563C1">R21</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-19-360.html__;!5Xm4_O-4tfk!lot7OkGX4V_KPbVj0ANCKif2DAw2-sP_FIeyTxIuNSGyExmCTAAtut4P3fiJkmebjOoekAyc6M81xKDvGbI$" target="_blank"><span style="color:#0563C1">R01</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">These Funding Opportunity Announcements encourage research on how the healthcare delivery system enhances or inhibits the effectiveness of a provider’s recommendation of the adolescent
human papillomavirus (HPV) vaccine. Characteristics of the provider, parent/patient, and clinical setting, can all affect whether a provider makes a recommendation, and whether that recommendation results in uptake of the HPV vaccine. This research requires
expertise in cancer prevention, adult and childhood behavior, immunization promotion, and healthcare delivery.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">First due date for R03 and R21: October 16, 2019. First due date for R01: October 17, 2019. Then standard dates apply. Expires September 8, 2022.
<span style="color:red">Med-RA deadline to receive draft documents for October 2019 due dates: October 3, 2019.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-19-356.html__;!5Xm4_O-4tfk!lot7OkGX4V_KPbVj0ANCKif2DAw2-sP_FIeyTxIuNSGyExmCTAAtut4P3fiJkmebjOoekAyc6M81INkiXRM$" target="_blank"><span style="color:#0563C1">NCI Clinical and Translational Exploratory/Developmental Studies (R21
Clinical Trial Optional)</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This Funding Opportunity Announcement supports the development of new exploratory research in cancer diagnosis, treatment, imaging, symptom/toxicity, and prevention clinical trials; correlative
studies associated with clinical trials; novel cancer therapeutic, symptom/toxicity, and preventive agent development, radiotherapy development activities, and mechanism-driven combinations; innovative preclinical studies, including the use of new clinically-relevant
models and imaging technologies, which could lead to first-in-human clinical trials, and therapeutic outcome disparities, including biomarkers or genetic/epigenetic signatures, among diverse racial/ethnic populations, including genetically engineered mouse
models, patient-derived xenograft models, organoids, and cell lines.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The R21 mechanism is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may
involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research (pre-clinical or clinical).<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due October 18, 2019; February 20, 2020, June 19, 2020; October 20, 2020; February 19, 2021; June 21, 2021; October 20, 2021; February 22, 2022; and June 21, 2022.
<span style="color:red">Med-RA deadline to receive draft documents for October 2019 due date: October 7, 2019.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Neural Regulation of Cancer (R21 / R01 Clinical Trial Not Allowed)<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-19-354.html__;!5Xm4_O-4tfk!lot7OkGX4V_KPbVj0ANCKif2DAw2-sP_FIeyTxIuNSGyExmCTAAtut4P3fiJkmebjOoekAyc6M81ntxmFUw$" target="_blank"><span style="color:#0563C1">R21</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-19-353.html__;!5Xm4_O-4tfk!lot7OkGX4V_KPbVj0ANCKif2DAw2-sP_FIeyTxIuNSGyExmCTAAtut4P3fiJkmebjOoekAyc6M81m6C-Mvo$" target="_blank"><span style="color:#0563C1">R01</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">These Funding Opportunity Announcements encourage collaborative, transdisciplinary research with both neuroscience and cancer research elements, which together will advance our current
understanding of the nervous system’s contribution to cancer. Leveraging the knowledge, tools, experimental models and reagents in neuroscience research to uncover novel mechanisms used by the nervous system to promote tumor initiation, progression and metastasis
can ultimately inform key areas of cancer research including the prevention and treatment of non-central nervous system tumors.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due October 21, 2019; May 27, 2020; October 21, 2020; May 27, 2021; October 21, 2021; and May 27, 2022.
<span style="color:red">Med-RA deadline to receive draft documents for October 2019 due date: October 8, 2019.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-HD-20-020.html__;!5Xm4_O-4tfk!lot7OkGX4V_KPbVj0ANCKif2DAw2-sP_FIeyTxIuNSGyExmCTAAtut4P3fiJkmebjOoekAyc6M81MYf3ZrE$" target="_blank"><span style="color:#0563C1">Using Archived Data and Specimen Collections to Advance
Maternal and Pediatric HIV/AIDS Research (R21 Clinical Trial Not Allowed)</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black">The purpose of this Funding Opportunity Announcement (FOA) is to address the needs of the maternal and pediatric HIV scientific community for research data translation and
sharing. This initiative will support secondary data analyses using archived HIV/AIDS data and specimens to generate new research questions and findings relevant to the scientific mission and priorities of the NICHD, Maternal and Pediatric Infectious Disease
Branch (MPIDB) and Office of AIDS Research (OAR). The goal of this initiative is to continue the encouragement of the scientific community to utilize HIV/AIDS archived data sets and specimen collections to answer important questions about the epidemiology,
pathogenesis, treatment, clinical manifestations and complications of HIV/AIDS in maternal, pediatric and adolescent populations.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:black">Due November 1, 2019.
</span></b><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents: October 21, 2019.</span></b><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-19-361.html__;!5Xm4_O-4tfk!lot7OkGX4V_KPbVj0ANCKif2DAw2-sP_FIeyTxIuNSGyExmCTAAtut4P3fiJkmebjOoekAyc6M81lx0xwDU$" target="_blank"><span style="color:#0563C1">Small Cell Lung Cancer (SCLC) Consortium: Biology, Therapy and Resistance
(U01 Clinical Trial Not Allowed)</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This Funding Opportunity Announcement (FOA) invites applications for research projects to join the Small-Cell Lung Cancer (SCLC) Consortium. Goals of the SCLC Consortium pertinent to this
FOA are: 1) to learn the mechanistic and biological underpinnings of SCLC formation, progression and heterogeneity; 2) to investigate how molecular vulnerabilities could be used to develop targeted agents or combinations; and 3) to understand clinical resistance
to drug and radiation therapy and its rapid development.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due November 12, 2019; March 11, 2020; November 12, 2020; March 11, 2021; November 12, 2021; and March 11, 2022.
<span style="color:red">Med-RA deadline to receive draft documents for November 2019 due date: October 29, 2019.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-20-021.html__;!5Xm4_O-4tfk!lot7OkGX4V_KPbVj0ANCKif2DAw2-sP_FIeyTxIuNSGyExmCTAAtut4P3fiJkmebjOoekAyc6M81HfYoWfA$" target="_blank"><span style="color:#0563C1">Trans-Agency Blood-Brain Interface Program (R61 / R33 – Clinical
Trials Not Allowed)</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of this Funding Opportunity Announcement (FOA) is to support high risk/high reward research on the blood/vascular component and regulation of the neurovascular-blood unit (a.k.a.,
Blood-Brain Barrier; BBB) in normal and pathological states to create enhanced/modified platforms that more closely model the human BBB. Research addressing vascular, hemostatic, hematopoietic, and/or immune cell interaction across the Blood-Brain Interface
is of particular interest. This initiative will serve to stimulate the development of a new field of science and re-define the neurovascular unit to also include the blood/vascular component to develop the next generation of pre-clinical human cellular model
systems of the human BBB to complement research currently based on animal models.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due December 2, 2019 and October 19, 2020.
<span style="color:red">Med-RA deadline to receive draft documents for December 2019 due date: November 18, 2019.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Myeloid-Derived Suppressor Cells (MDSCs) as Potential Therapeutic Targets in TB/HIV (R21 Clinical Trial Not Allowed)<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-19-364.html__;!5Xm4_O-4tfk!lot7OkGX4V_KPbVj0ANCKif2DAw2-sP_FIeyTxIuNSGyExmCTAAtut4P3fiJkmebjOoekAyc6M81fKmo70M$" target="_blank"><span style="color:#0563C1">R21</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/par-19-357.html__;!5Xm4_O-4tfk!lot7OkGX4V_KPbVj0ANCKif2DAw2-sP_FIeyTxIuNSGyExmCTAAtut4P3fiJkmebjOoekAyc6M81rM6H3C8$" target="_blank"><span style="color:#0563C1">R01</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for support of innovative clinical, preclinical and non-clinical research to determine the potential
of MDSCs as a target for host-directed therapeutics for tuberculosis in the context of HIV co-infection, and to better understand the role of host-induced immunosuppression in the progression of
<i>Mycobacterium tuberculosis</i> pathogenesis.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due January 8, 2020; January 8, 2021; and January 10, 2022.
<span style="color:red">Med-RA deadline to receive draft documents for January 2020 due date: December 16, 2019.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://www.nsf.gov/funding/pgm_summ.jsp?pims_id=505715__;!5Xm4_O-4tfk!lot7OkGX4V_KPbVj0ANCKif2DAw2-sP_FIeyTxIuNSGyExmCTAAtut4P3fiJkmebjOoekAyc6M812OMfLCw$" target="_blank"><span style="color:#0563C1">NSF's Accountable Institutions and Behavior (AIB)</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The Accountable Institutions and Behavior (AIB) Program supports basic scientific research that advances knowledge and understanding of issues broadly related to attitudes, behavior, and
institutions connected to public policy and the provision of public services. Research proposals are expected to be theoretically motivated, conceptually precise, methodologically rigorous, and empirically oriented. Substantive areas include (but are not limited
to) the study of individual and group decision-making, political institutions (appointed or elected), attitude and preference formation and expression, electoral processes and voting, public administration, and public policy. This work can focus on a single
case or can be done in a comparative context, either over time or cross-sectionally. The Program does not fund applied research. The Program also supports research experiences for undergraduate students and infrastructural activities, including methodological
innovations. In addition, we encourage you to examine the websites for the National Science Foundation’s Law and Science (LS) and Security and Preparedness (SAP) programs.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due January 15, 2020 and August 17, 2020.
<span style="color:red">Med-RA deadline to receive draft documents for January 2020 due date: January 2, 2020.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-19-019.html__;!5Xm4_O-4tfk!lot7OkGX4V_KPbVj0ANCKif2DAw2-sP_FIeyTxIuNSGyExmCTAAtut4P3fiJkmebjOoekAyc6M81ymKz46k$" target="_blank"><span style="color:#0563C1">Food as Medicine: Food Insecurity and HIV-related Comorbidities,
Coinfections, and Complications within the Mission of the NIDDK (R01 Clinical Trial Optional)</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This funding opportunity announcement (FOA) seeks US domestic research projects that address how food insecurity effects HIV comorbidities, coinfections, and complications (CCCs) within
the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The approaches may address the pathways linking food insecurity and the development or exacerbation of CCCs; or they may evaluate the mechanisms whereby interventions
that alleviate food insecurity improve CCCs. These mechanisms could be related to nutritional inadequacies or patient health-related behaviors.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due March 9, 2020.
<span style="color:red">Med-RA deadline to receive draft documents: February 25, 2020.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:black">To search for additional funding opportunities, please visit </span></b><span style="font-size:12.0pt;font-family:Palatino;color:black"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV6980C-DCl-AxzFLHMVYQ&e=" title="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV69"><b><span style="color:red">CoM’s
unofficial funding opportunities blog</span></b></a></span><b><span style="font-size:12.0pt;font-family:Palatino;color:red">.</span></b><o:p></o:p></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt"><o:p> </o:p></span></p>
</div>
</body>
</html>